# US 2021/0332019 A1 · Bicyclic Compound as a Caspase Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332019 A1
- Document ID: US20210332019A1
- Status: Published application
- Kind: A1
- Application number: 16/479,673
- Filed: 2018-01-23
- Published: 2021-10-28
- Earliest claimed: 2017-01-23
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Inventors: Jianfeng MOU; Songliang WU; Haiying HE; Fengying GUO; Chuan WANG; Jie LI; Jian LI; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20210332019A1

## CPC

- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07K 5/06139: {with the first amino acid being heterocyclic}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 263/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.

## Claims

### Claim 1

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof,
wherein,
ring A is selected from a 5- or 6-membered heteroaryl group which is optionally substituted with ring B is selected from phenyl or C3-6 cycloalkyl, which is optionally substituted with R;
R is selected from halogen, OH, NH2, or a C1-3 alkyl group optionally substituted with 1, 2 or 3 R1;
R1 is selected from F, Cl, Br, I, OH, NH2, NH(CH3) or N(CH3)2.

### Claim 2 (depends on 1)

The Compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein a heteroatom of ring A is independently selected from 0, S or N, and number of the heteroatom of ring A is selected from 1, 2 or 3.

### Claim 3 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein ring A is selected from oxazolyl, isoxazolyl, imidazolyl, thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl or pyrazolyl.

### Claim 4 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein ring A is selected from

### Claim 5 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein ring B is selected from phenyl or cyclohexyl, which is optionally substituted with R.

### Claim 6 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein R is selected from F, Cl, Br, I, OH, NH2, or Me or Et optionally substituted with 1, 2 or 3 R1.

### Claim 7 (depends on 6)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 6, wherein R is selected from F, Cl, Br, I, OH, NH or CF3.

### Claim 8 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein ring B is selected from

### Claim 9 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according claim 1, wherein
is selected from
and ring B is optionally substituted with R.

### Claim 10 (depends on 1)

The compound the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein
is selected from

### Claim 11 (depends on 10)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 10, wherein
is selected from

### Claim 12 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein
is selected from

### Claim 13 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein the compound is represented by the following formulae,

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, and a pharmaceutically acceptable carrier or excipient.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method of preventing or treating caspase receptor related diseases in a mammal, comprising administering a therapeutically effective amount of the compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1 to the mammal in need thereof.

### Claim 17 (depends on 6)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 6, wherein R is selected from F, Cl, Br, I, OH, NH2, or Me optionally substituted with 1, 2 or 3 R1, and wherein R1 is selected from F, Cl, Br or I.

### Claim 18 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein R is selected from F, Cl, Br, I, OH, NIH, or Me or Et optionally substituted with 1, 2 or 3 F.

### Claim 19 (depends on 18)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 18, wherein R is selected from F, Cl, Br, I, or Me optionally substituted with 1, 2 or 3 F.

### Claim 20 (depends on 7)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 7, wherein R is selected from F, Cl, Br, I or CF3.

### Claim 21 (depends on 1)

The compound, the pharmaceutically acceptable salt or tautomer thereof according to claim 1, wherein the compound is selected from a compound of formula (II),
